|Over a month ago|
Nephros reports Q1 EPS (6c), consensus (12c) » 17:4905/0605/06/21
Reports Q1 revenue…
Reports Q1 revenue $2.74M, consensus $2.55M. "Fiscal year 2021 started strong as we reached our highest first-quarter revenue in company history," said Andy Astor, CEO of Nephros. "All elements within our water filtration business showed strength, including new customer acquisition, recurring revenue, and emergency response. Our $2.7 million first-quarter revenue represents an 8% increase over the same period last year, and 17% growth over our prior quarter."
Nephros reports preliminary Q1 revenue $2.7M, consensus $2.35M » 07:3404/0504/05/21
"Despite the pandemic, Nephros accomplished a milestone, recording the highest ever, first-quarter revenue, and the third-highest quarterly revenue in our history. These results, represented by strength in all of our filtration markets - Healthcare, Dialysis, and Commercial - reflect the growth of our underlying business and steady, long-term focus on taking care of our strategic partners and customers," said Andy Astor, CEO of Nephros. "As more of the country is vaccinated over the coming weeks and months, we anticipate increasingly open markets and a return to pre-pandemic growth rates." Nephros ended the first quarter with approximately $8.1M in cash on a consolidated basis.
|Over a quarter ago|
Nephros reports Q4 revenue $2.3M, consensus $2.34M » 16:2603/0103/01/21
Reports Q4 adjusted…
Reports Q4 adjusted EBITDA ($466,000). As of December 31, 2020, Nephros had cash and cash equivalents of approximately $8.2M. "While 2020 was a challenging year overall, we were pleased to deliver consecutive quarter-over-quarter growth in the second half," said Andy Astor, CEO of Nephros. "The two hardest hit segments of our business were new customer acquisitions and emergency response, offset by stable recurring revenue from our existing customer base, limiting our overall downturn for the year to 17%. As COVID-19 immunity increases over the coming weeks and months, we are optimistic that our business will return to pre-pandemic growth levels in the latter half of this year."
Nephros appoints Wes Lobo as CMO » 07:3902/1802/18/21
Nephros (NEPH) announced…
Nephros (NEPH) announced the appointment of Wes Lobo as CMO, reporting directly to Nephros CEO, Andy Astor. In this role, Wes will be responsible for driving the company's strategic growth through innovative solutions, go-to-market strategies, and marketing. Wes joins Nephros after recently serving as Vice President of Marketing and New Product Development at Watts Water Technologies (WTS), a leader in plumbing, heating, and water quality products and services for residential, commercial, and general industrial markets.
Nephros initiated with a Buy, $12.50 target at B. Riley Securities » 08:1801/2601/26/21
B. Riley Securities…
B. Riley Securities analyst Marc Wiesenberger initiated coverage of Nephros with a Buy rating and $12.50 price target. The company provides proprietary ultrafiltration technology for water systems primarily to hospital and healthcare customer end markets, with "burgeoning opportunities" for application in the larger commercial sector, Wiesenberger tells investors in a research note. Additionally, Nephros is in the process of seeking FDA clearance for its second-generation hemodiafiltration product for dialysis patients, which is a "low-cost, real option" to the company's established operations, says the analyst. He expects Nephros to return to growth as the environment normalizes in the second half of 2021.
Nephros initiated with a Buy at B. Riley Securities » 05:2001/2601/26/21
B. Riley Securities…
B. Riley Securities initiated coverage of Nephros with a Buy rating and $12.50 price target.
Nephros reports preliminary 2020 revenue $8.5M, consensus $8.56M » 07:3501/1201/12/21
Nephros ended the year…
Nephros ended the year with approximately $8.3M in cash on a consolidated basis.
Nephros reports preliminary Q4 revenue $2.3M, consensus $2.31M » 07:3401/1201/12/21
"As we have…
"As we have referenced previously, COVID-19's impact on our revenues was significant in 2020, particularly with respect to new customer acquisition, emergency outbreak response, and hotel and restaurant sales," said Andy Astor, President and CEO of Nephros. "As the world has begun to adapt to the pandemic, however, our revenues have consistently improved, with sequential quarter-over-quarter gains in both Q3 and Q4. We are optimistic that this trend will continue as we enter 2021, and that our return to high growth rates will be associated with broad vaccine distribution in the coming months."
Nephros expects to file HDF2 Special 510(k) in early 2021 » 07:4601/0401/04/21
Nephros provides an…
Nephros provides an update to the second-generation HDF Assist Module program being developed and commercialized through its majority-owned subsidiary, Specialty Renal Products Inc. announces the granting of a patent that covers technology utilized in HDF2, and announces expanded heat disinfection product capabilities. "We are very pleased to announce today that the HDF2 technology is now complete, after delays in prior quarters," said Daron Evans, President of SRP. "As part of our commercial launch preparations, however, we have decided to postpone the HDF2 Special 510(k) filing a few weeks into the new year. We are scaling-up our supply chain and manufacturing capability to support expected future growth and believe that our filing will be stronger if we include details on these manufacturing plans in our submission. As a result of this decision, we will miss our self-declared deadline of filing by the end of 2020, a decision we do not take lightly. However, we do not believe this delay will materially impact either near-term revenue potential or the strategic potential of HDF2, due to the continuing impact of the COVID-19 pandemic on the dialysis industry. We believe that a commercial launch of HDF2 into dialysis clinics will not be possible until after the nation is mostly through the COVID-19 vaccination process, in mid-2021 at the earliest." On November 3, 2020, Nephros was officially granted US Patent 10,821,216: Method and Apparatus for Hemodiafiltration Module for use with a Dialysis Machine. The patent covers certain aspects of the circuit used to generate substitution fluid from the dialysate generated by a hemodialysis machine. The EndoPur product line was launched in 2019 to provide ultrafiltration to large loop dialysis clinic water systems. At the time of launch, Nephros validated the product only for cold-water systems that use chemicals for routine water line disinfection. Nephros announced that we have updated the EndoPur product to withstand routine heat disinfection up to 85degreesC. Since cold-water disinfection is used in less than half of dialysis clinics, this product update has the potential to double the addressable market for these filtration solutions. Nephros also announced that the S100 product line has also been validated for heat disinfection. S100 filters provide protection from legionella and other harmful waterborne pathogens at sinks and showers. At hospitals and other medical facilities, they are used to retain these waterborne pathogens and to purify water used for washing and drinking. Hot water lines are particularly susceptible to pathogen growth because heat reduces chlorine levels, which otherwise provide chemical prevention from bacterial growth. By validating heat disinfection on our S100 product line, Nephros provides additional confidence to customers that Nephros products withstand the rigors of the real-world environment, including heat disinfection.
Sidoti to hold a virtual conference » 08:4811/1911/19/20
ACU, ALCO, AP, BWEN, CRAI, CTG, DRAD, INFU, III, NEPH, MYO, TUP, TREC, TNXP, VNRX, PIXY, RICK, STRT, SWKH, TESS, VRME, WYY
Sidoti Virtual Microcap…
Sidoti Virtual Microcap Conference will be held on November 19.